OYST
Oyster Point Pharma, Inc. [OYST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
OYST Stock Summary
In the News
OYST Financial details
Company Rating
Neutral
Market Cap
0
Income
-188.97M
Revenue
19.58M
Book val./share
-0.83
Cash/share
2.56
Dividend
-
Dividend %
-
Employees
303
Optionable
No
Shortable
Yes
Earnings
24 Feb 2023
P/E
-2.08
Forward P/E
-
PEG
-0.14
P/S
-
P/B
-13.5
P/C
-
P/FCF
-
Quick Ratio
2.81
Current Ratio
3.35
Debt / Equity
-4.27
LT Debt / Equity
-4.24
-
-
EPS (TTM)
-7.11
EPS next Y
-
EPS next Q
-
EPS this Y
37.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
19.13%
EPS Q/Q
-24.62%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
1%
ROA
-132%
ROE
-971%
ROC
-1.56%
Gross Margin
77%
Oper. Margin
-961%
Profit Margin
-1111%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.46-13.45
52W High
-
52W Low
-
RSI
-
Rel Volume
5
Avg Volume
417.56K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
OYST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0.94 | |
| Net income per share | -0.73 | -1.83 | -9.97 | -2.92 | -4.01 | |
| Operating cash flow per share | -0.52 | -1.89 | -8.9 | -2.42 | -3.43 | |
| Free cash flow per share | -0.52 | -1.89 | -8.95 | -2.45 | -3.49 | |
| Cash per share | 2.47 | 0.58 | 30.35 | 7.98 | 7.43 | |
| Book value per share | -2.43 | -4.24 | 29.94 | 7.74 | 3.82 | |
| Tangible book value per share | -2.43 | -4.24 | 29.94 | 7.74 | 3.82 | |
| Share holders equity per share | -2.43 | -4.24 | 29.94 | 7.74 | 3.82 | |
| Interest debt per share | 0.05 | 0 | 0.18 | 0.03 | 3.7 | |
| Market cap | 169.46M | 169.46M | 112.06M | 454.1M | 475.45M | |
| Enterprise value | 147.15M | 164.3M | -26.28M | 262.2M | 374.81M | |
| P/E ratio | -25.67 | -10.27 | -2.45 | -6.44 | -4.55 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 19.38 | |
| POCF ratio | -36.26 | -9.92 | -2.75 | -7.78 | -5.32 | |
| PFCF ratio | -36.26 | -9.92 | -2.73 | -7.68 | -5.23 | |
| P/B Ratio | -7.74 | -4.43 | 0.82 | 2.43 | 4.78 | |
| PTB ratio | -7.74 | -4.43 | 0.82 | 2.43 | 4.78 | |
| EV to sales | 0 | 0 | 0 | 0 | 15.27 | |
| Enterprise value over EBITDA | -24.07 | -9.96 | 0.58 | -3.74 | -3.87 | |
| EV to operating cash flow | -31.48 | -9.62 | 0.64 | -4.49 | -4.19 | |
| EV to free cash flow | -31.48 | -9.62 | 0.64 | -4.44 | -4.13 | |
| Earnings yield | -0.04 | -0.1 | -0.41 | -0.16 | -0.22 | |
| Free cash flow yield | -0.03 | -0.1 | -0.37 | -0.13 | -0.19 | |
| Debt to equity | 0 | 0 | 0.01 | 0 | 0.93 | |
| Debt to assets | 0 | 0 | 0.01 | 0 | 0.42 | |
| Net debt to EBITDA | 3.65 | 0.31 | 3.03 | 2.74 | 1.04 | |
| Current ratio | 11.21 | 5.98 | 26.33 | 17.88 | 7.47 | |
| Interest coverage | -11.65 | 0 | 0 | 0 | -25.96 | |
| Income quality | 0.71 | 1.04 | 0.89 | 0.83 | 0.89 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 1.66 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0.99 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0.02 | |
| Capex to revenue | 0 | 0 | 0 | 0 | -0.06 | |
| Capex to depreciation | 0 | 0 | -10.53 | -1.52 | -10.53 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.49 | |
| Graham number | 6.32 | 13.21 | 81.96 | 22.55 | 18.57 | |
| ROIC | 0.26 | 0.44 | -0.35 | -0.38 | -0.52 | |
| Return on tangible assets | -0.28 | -2.89 | -0.32 | -0.36 | -0.47 | |
| Graham Net | -2.52 | -4.29 | 29.06 | 7.52 | 3.01 | |
| Working capital | 21.11M | 4.68M | 136.78M | 185.39M | 186.45M | |
| Tangible asset value | -21.89M | -38.24M | 137.3M | 186.66M | 99.54M | |
| Net current asset value | -21.89M | -38.33M | 136.27M | 185.12M | 92.17M | |
| Invested capital | 0 | 0 | 0.01 | 0 | 0.93 | |
| Average receivables | 0 | 0 | 0 | 0 | 3.33M | |
| Average payables | 0 | 440K | 481K | 1.39M | 4.39M | |
| Average inventory | 0 | 0 | 0 | 0 | 3.04M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 99 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 1.55K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 1.46K | |
| Receivables turnover | 0 | 0 | 0 | 0 | 3.69 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0.23 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0.25 | |
| ROE | 0.3 | 0.43 | -0.33 | -0.38 | -1.05 | |
| Capex per share | 0 | 0 | -0.04 | -0.03 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.69 | 0.25 | 0.1 | 0.18 | 0.21 | |
| Net income per share | -0.68 | -1.71 | -1.91 | -1.99 | -1.5 | |
| Operating cash flow per share | -0.42 | -1.58 | -1.87 | -1.45 | -1.34 | |
| Free cash flow per share | -0.42 | -1.59 | -1.87 | -1.46 | -1.34 | |
| Cash per share | 7.07 | 7.38 | 5.38 | 3.92 | 2.56 | |
| Book value per share | 5.28 | 3.8 | 2.1 | 0.4 | -0.83 | |
| Tangible book value per share | 5.28 | 3.8 | 2.1 | 0.4 | -0.83 | |
| Share holders equity per share | 5.28 | 3.8 | 2.1 | 0.4 | -0.83 | |
| Interest debt per share | 1.68 | 3.64 | 3.62 | 3.64 | 3.66 | |
| Market cap | 308.55M | 478.25M | 309.99M | 115.8M | 150.79M | |
| Enterprise value | 166.96M | 377.61M | 259.98M | 105.07M | 176.71M | |
| P/E ratio | -4.37 | -2.68 | -1.52 | -0.55 | -0.94 | |
| Price to sales ratio | 17.2 | 72.51 | 114.64 | 24.68 | 26.97 | |
| POCF ratio | -28.54 | -11.53 | -6.24 | -2.98 | -4.19 | |
| PFCF ratio | -27.88 | -11.47 | -6.23 | -2.97 | -4.19 | |
| P/B Ratio | 2.24 | 4.8 | 5.54 | 10.75 | -6.79 | |
| PTB ratio | 2.24 | 4.8 | 5.54 | 10.75 | -6.79 | |
| EV to sales | 9.31 | 57.25 | 96.15 | 22.39 | 31.61 | |
| Enterprise value over EBITDA | -10.11 | -9.58 | -5.81 | -2.25 | -5.33 | |
| EV to operating cash flow | -15.45 | -9.1 | -5.23 | -2.71 | -4.91 | |
| EV to free cash flow | -15.09 | -9.05 | -5.22 | -2.7 | -4.91 | |
| Earnings yield | -0.06 | -0.09 | -0.16 | -0.46 | -0.27 | |
| Free cash flow yield | -0.04 | -0.09 | -0.16 | -0.34 | -0.24 | |
| Debt to equity | 0.31 | 0.93 | 1.67 | 8.74 | -4.27 | |
| Debt to assets | 0.22 | 0.42 | 0.53 | 0.65 | 0.87 | |
| Net debt to EBITDA | 8.58 | 2.55 | 1.12 | 0.23 | -0.78 | |
| Current ratio | 12.51 | 7.47 | 7.27 | 4.26 | 3.35 | |
| Interest coverage | -14.92 | -15.12 | -14.62 | -14.82 | -9.51 | |
| Income quality | 0.61 | 0.99 | 1.04 | 0.78 | 0.98 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 1.95 | 4.78 | 2.98 | 2.17 | |
| Research and developement to revenue | 0.35 | 0.83 | 1.73 | 0.99 | 0.7 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.01 | 0 | 0 | 0 | |
| Capex to revenue | -0.01 | -0.04 | -0.03 | -0.03 | 0 | |
| Capex to depreciation | -7.11 | -4.7 | -1.15 | -1.04 | 0 | |
| Stock based compensation to revenue | 0.17 | 0.47 | 1.61 | 0.89 | 0.67 | |
| Graham number | 8.98 | 12.08 | 9.51 | 4.24 | 5.28 | |
| ROIC | -0.09 | -0.21 | -0.31 | -0.46 | -0.49 | |
| Return on tangible assets | -0.09 | -0.2 | -0.29 | -0.37 | -0.37 | |
| Graham Net | 4.94 | 2.99 | 1.09 | -0.63 | -1.84 | |
| Working capital | 174.53M | 186.45M | 144.33M | 101.58M | 68.51M | |
| Tangible asset value | 137.51M | 99.54M | 55.99M | 10.78M | -22.2M | |
| Net current asset value | 132.19M | 92.17M | 46.63M | -443K | -33.7M | |
| Invested capital | 0.31 | 0.93 | 1.67 | 8.74 | -4.27 | |
| Average receivables | 1.25M | 4.58M | 6.2M | 8.33M | 12.05M | |
| Average payables | 2.92M | 5M | 4.55M | 3.66M | 4.43M | |
| Average inventory | 0 | 3.04M | 5.09M | 5.37M | 6.8M | |
| Days sales outstanding | 12.54 | 90.82 | 190.92 | 209.38 | 212.23 | |
| Days payables outstanding | 0 | 383.37 | 695.36 | 324.27 | 276.74 | |
| Days of inventory on hand | 0 | 359.17 | 1.1K | 456.53 | 464.62 | |
| Receivables turnover | 7.18 | 0.99 | 0.47 | 0.43 | 0.42 | |
| Payables turnover | 0 | 0.23 | 0.13 | 0.28 | 0.33 | |
| Inventory turnover | 0 | 0.25 | 0.08 | 0.2 | 0.19 | |
| ROE | -0.13 | -0.45 | -0.91 | -4.93 | 1.81 | |
| Capex per share | -0.01 | -0.01 | 0 | 0 | 0 |
OYST Frequently Asked Questions
What is Oyster Point Pharma, Inc. stock symbol ?
Oyster Point Pharma, Inc. is a US stock , located in Princeton of New jersey and trading under the symbol OYST
What is Oyster Point Pharma, Inc. stock quote today ?
Oyster Point Pharma, Inc. stock price is $- today.
Is Oyster Point Pharma, Inc. stock public?
Yes, Oyster Point Pharma, Inc. is a publicly traded company.
Company Profile
- Volume Average 417.56K
- Employee 303
- CEO Dr. Jeffrey Nau
- Headquarters Princeton,NEW JERSEY,US
- IPO Date 2019-10-31
-
Website
https://www.oysterpointrx.com 
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
